Page 266 - 2021_07-Haematologica-web

mutation can be regarded as particular subgroup of WM.
Hélène Vergneault,1 Djaouida Bengoufa,2
Aline Frazier-Mironer,3 Isabelle Brocheriou,4 Samuel Bitoun,1 Camille Villesuzanne,1 Alexis Talbot,1,5 Stéphanie Harel,1 Bertrand Arnulf1 and Bruno Royer1
1Immuno-hematology Department, Saint-Louis Hospital, APHP;
2Immunology Laboratory, Saint-Louis Hospital, APHP; 3Rheumatology
Department, Lariboisière Hospital, APHP; 4Pathology Laboratory, La
RNA splice accounting for a mu heavy chain disease protein. Proc
Natl Acad Sci U S A. 1986;83(8):2689-2693.
4. Seligmann M, Mihaesco E, Preud’homme J-L, Danon F, Brouet J-C.
Heavy chain diseases: current findings and concepts. Immunol Rev.
1979;48(1):145-167.
5. FermandJ-P,BrouetJ-C.Heavy-chaindiseases.HematolOncolClin
North Am. 1999;13(6):1281-1294.
6. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in
Waldenström’s macroglobulinemia. N Engl J Med. 2012;367(9):826-
Pitié Salpêtrière Hospital, APHP and 5INSERM U976 Équipe 5, 833.
Institut de Recherche Saint Louis, Université de Paris, Paris, France Correspondence: BRUNO ROYER - bruno.royer@aphp.fr doi:10.3324/haematol.2020.277137
Received: December 16, 2020.
Accepted: February 4, 2021.
Pre-published: February 18, 2021. Disclosures: no confilcts of interest to disclose.
Contributions: HV, BA and BR initiated the study, analyzed the data and wrote the manuscript; DB performed immunological analyzes; IB interpreted renal biopsy; HV, AT, SB, CV, BA, AFM, SH and BR took care of patients; and all authors analyzed the data, reviewed and approved the final manuscript.
References
1. Franklin EC, Lowenstein J, Bigelow B, Meltzer M. Heavy chain dis- ease. A new disorder of serum γ-globulins: report of the first case. Am J Med. 1964;37(3):332-350.
2. HendershotL,BoleD,KöhlerG,KearneyJF.Assemblyandsecretion of heavy chains that do not associate posttranslationally with immunoglobulin heavy chain-binding protein. J Cell Biol. 1987; 104(3):761-767.
3. Bakhshi A, Guglielmi P, Siebenlist U, Ravetch JV, Jensen JP, Korsmeyer SJ. A DNA insertion/deletion necessitates an aberrant
7. UppalNN,MongaD,VernaceMA,etal.Kidneydiseasesassociated with Waldenström macroglobulinemia. Nephrol Dial Transplant. 2019;34(10):1644-1652.
8. Presti BC, Sciotto CG, Marsh SG. Lymphocytic lymphoma with associated γ heavy chain and IgM-γ paraproteins: an unusual biclon- al gammopathy. Am J Clin Pathol.1990;93(1):137-141.
9. Wahner-Roedler DL, Kyle RA. m-heavy chain disease: presentation as a benign monoclonal gammopathy. Am J Hematol. 1992; 40(1): 56-60.
10. Leleu X, Xie W, Bagshaw M, et al. The role of serum immunoglob- ulin free light chain in response and orogression in Waldenstrom macroglobulinemia. Clin Cancer Res. 2011;17(9):3013-3018.
11.Itzykson R, Le Garff-Tavernier M, Katsahian S, Diemert M-C, Musset L, Leblond V. Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom’s macroglobuline- mia. Haematologica. 2008;93(5):793-794.
12. Preud’homme JL, Bauwens M, Dumont G, Goujon JM, Dreyfus B, Touchard G. Cast nephropathy in mu heavy chain disease. Clin Nephrol. 1997;48(2):118-121.
13. Kinoshita K, Yamagata T, Nozaki Y, et al. Mu-heavy chain disease associated with systemic amyloidosis. Hematol Amst Neth. 2004; 9(2):135-137.
14. Khamlichi AA, Aucouturier P, Preud’homme JL, Cogné M. Structure of abnormal heavy chains in human heavy-chain-deposition dis- ease. Eur J Biochem. 1995;229(1):54-60.
15. Witzig TE, Wahner-Roedler DL. Heavy chain disease. Curr Treat Options Oncol. 2002;3(3):247 254.
2036
haematologica | 2021; 106(7)
Case Reports